4h agoRevolution Medicines' pancreatic cancer drug candidate daraxonrasib receives standing ovation at ASCO clinical conferenceOver 40,000 oncologists, investors, and advocates attended the presentationSentimentSentimentPos100%Neg0%Users are celebrating RevMed earning a standing ovation at ASCO for its pancreatic cancer advance because such wins are rare and meaningful.4 comments with sentiment. View comments.